The GLP-1 RA, semaglutide, significantly reduces epilepsy risk in diabetes, and this protective signal is driven by pathways unrelated to improvements in A1c or body weight.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/semaglutide-tied-50-lower-risk-epilepsy-diabetes-2025a1000ynf?src=rss
Author :
Publish date : 2025-12-10 13:18:00
Copyright for syndicated content belongs to the linked Source.
